Cervomed Inc CRVO

$3.22 -0.06 (-1.83%)

Valuation

Market cap
48,683,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
PE ratio
0.00
Forward PE
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
237,300
Avg volume
275,478
Day's range
$3.17 – $3.34
Shares out
15,119,000
Stochastic %K
71%
Beta
-0.75
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

buymoremakemore Oct 12, 3:04 AM
$CRVO Found it! https://ir.cervomed.com/static-files/460782c3-134f-46d9-9386-4df5998ac11b
2 replies
Houseofsweeps Oct 11, 6:28 PM
$CRVO this is crazy still no news 😆😭
1 replies
buymoremakemore Oct 11, 3:19 PM
$CRVO is this it? I founs the abstract here: https://isftd2026.org/program/
2 replies
Pineapple567 Oct 11, 3:02 PM
$CRVO still no news?
1 replies
QuietPhase888 Oct 11, 9:09 AM
$CRVO One detail worth keeping in mind today: the 12-week biomarker data come from the open-label treatment period. The randomized withdrawal comparison comes later, after 24 weeks. The September announcement expanded the expected dataset from the original 8 patients to at least 22. I’m watching whether NfL/GFAP changes are consistent across patients, rather than driven by a few outliers. Encouraging biomarkers could support further development, but wouldn’t establish clinical benefit on their own. Long CRVO. Study design: https://clinicaltrials.gov/study/NCT07033481
0 replies
StellaLunaSun Oct 11, 8:00 AM
$CRVO 4 hours until the presentation. I'm keeping my fingers crossed for all of us. Don't forget, Cervomed is a super low floater. And no matter how things turn out today, I'm super positive for the company, because the guy from Vertex pharmaceuticals is involved and he's the one who made Vertex big. He knows his stuff and has been working on it for a very long time.
1 replies
Marcos125 Oct 11, 5:44 AM
$CRVO CRVO Conference Session Today Sunday, October 11, 2026 Part of the ISFTD 2026 conference in Philadelphia 8:30 – 10:30 AM EDT Presentation Topic: Preliminary biomarker results from the Phase 2a trial of neflamapimod for the treatment of a type of dementia known as nfvPPA.
0 replies
Houseofsweeps Oct 11, 1:10 AM
$CRVO good luck to us all tomorrow! In August they reported the first 8 as “very encouraging” 🤞
0 replies